Skip to main content

Table 1 Effect of a 2-week course of LZ administration on physiological serum and urine characteristics of NOD and db/db mice

From: Lysozyme Enhances Renal Excretion of Advanced Glycation Endproducts In Vivo and Suppresses Adverse AGE-mediated Cellular Effects In Vitro: A Potential AGE Sequestration Therapy for Diabetic Nephropathy?

  

NOD (n = 5)

 

db/db (n = 5)

Treatment (LZ)

SJL (n = 10)

Baseline

2-Weeks

db/m (n = 10)

Baseline

2-Weeks

Weight (g)

25 ± 3

25.3 ± 2.4

26.8 ± 1.6

26.7 ± 2.8

48.9 ± 1.5

50.1 ± 1.6

Blood glucose (mg/dL)

117 ± 44

128 ± 20

132 ± 32

121 ± 27

320 ± 130

290 ± 60

Serum AGE (U/ml)

14.2 ± 4.8

31.5 ± 6.7

22.3 ± 5.1*

21.5 ± 7.7

37.9 ± 3.8

26.2 ± 5.3*

Serum Cr (mg/dL)

0.38 ± 0.04

0.42 ± 0.02

0.47 ± 0.05

0.33 ± 0.06

0.69 ± .01#

0.72 ± 0.11##

Urine AGE (U/ml)

197 ± 41

200.3 ± 71.4

367.9 ± 41.2*

103.8 ± 37.5

92.7 ± 52.6

170.9 ± 49.5*

Urine Cr (ug/ml)

357.3 ± 77.9

308.4 ± 68.7

324.9 ± 50.3

276.5 ± 93.4

207.6 ± 31.7

212.3 ± 49.4

Ccr (ml/min)

0.03 ± 0.01

0.04 ± 0.008

0.05 ± 0.007

0.05 ± 0.02

0.05 ± 0.007

0.05 ± 0.01

CAGE (ml/min)

0.004 ± 0.0012

0.003 ± 0.0011

0.008 ± 0.0009**

0.003 ± 0.001

0.004 ± 0.002

0.013 ± 0.004**

Urinary Alb/Cr

0.29 ± 0.15

0.92 ± 0.32##

0.53 ± 0.24*

0.38 ± 0.2

1.13 ± 0.45

0.73 ± 0.26*

  1. *p < 0.05, **p < 0.01, 2 weeks LZ vs baseline. #p < 0.05, ##p < 0.01, vs respective control group.